How large is the paraganglioma market, and what is its growth trajectory?
The paraganglioma market size has grown strongly in recent years. It will grow from $2.89 billion in 2024 to $3.03 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to advancements in diagnostic imaging, increasing awareness & screening programs, regulatory approvals for targeted therapies, growth in specialized treatment centers, and advancements in genetic testing.
The paraganglioma market size is expected to see strong growth in the next few years. It will grow to $3.64 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to emerging targeted therapies & immunotherapies, expansion of radiopharmaceuticals, rising prevalence of genetic disease, growing investments in rare disease research, and improved healthcare access in emerging markets. Major trends in the forecast period include advancements in targeted therapies, expansion of radiopharmaceuticals, the rise of immunotherapy approaches, improved artificial intelligence (AI) in diagnostics, and the development of minimally invasive surgical techniques.
Get Your Free Sample of The Global Paraganglioma Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21245&type=smp
What are the key forces behind the paraganglioma market’s growth in recent years?
The increasing investments on oncology research and medicine is expected to propel the growth of the paraganglioma market going forward. Investments in oncology research and medicine refer to financial allocations made by governments, pharmaceutical companies, research institutions, and private investors to advance the understanding, prevention, diagnosis, and treatment of cancer. The increasing investments in oncology research and medicine are due to the rising global cancer burden, advancements in precision medicine, growing demand for innovative therapies, expanding clinical trials, government and private funding initiatives, and the development of targeted and immunotherapy treatments. Investments in oncology research and medicine support paraganglioma by driving advancements in early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, improving pediatric cancer care infrastructure, and fostering innovative research to better understand the disease’s biology and progression. For instance, in May 2024, according to the IQVIA, an India-based information technology company providing advanced analytics, global spending on cancer medicine rose to $223 billion in 2023, marking a $25 billion increase from 2022, and is expected to reach $409 billion by 2028. Therefore, the increasing investments on oncology research and medicine drives the paraganglioma market.
What are the major segments of the paraganglioma market?
The paraganglioma market covered in this report is segmented –
1) By Type: Sympathetic Paragangliomas, Parasympathetic Paragangliomas, Caroid Paragangliomas, Cervical Paragangliomas, Jugular Paragangliomas, Secretory Paragangliomas, Temporal Paragangliomas
2) By Origin: Head And Neck, Abdomen, Pelvis, Other Origins
3) By Treatment Type: Peptide Receptor Radionuclide Therapy, Surgery, Chemotherapy, Radiation Therapy, Other Treatment Types
4) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes, Other End-Users
Subsegments:
1) By Sympathetic Paragangliomas: Adrenal Sympathetic Paragangliomas, Extra-Adrenal Sympathetic Paragangliomas
2) By Parasympathetic Paragangliomas: Head And Neck Parasympathetic Paragangliomas, Thoracic Parasympathetic Paragangliomas
3) By Carotid Paragangliomas: Unilateral Carotid Paragangliomas, Bilateral Carotid Paragangliomas
4) By Cervical Paragangliomas: Vagal Paragangliomas, Hypoglossal Paragangliomas
5) By Jugular Paragangliomas: Type A, Type B, Type C, Type D
6) By Secretory Paragangliomas: Catecholamine-Secreting Paragangliomas, Non-Catecholamine-Secreting Paragangliomas
7) By Temporal Paragangliomas: Tympanic Paragangliomas, Mastoid Paragangliomas
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report
Which companies dominate the paraganglioma market?
Major companies operating in the paraganglioma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc. , Mount Sinai, Penn Medicine, Stanford Health Care, St. Jude Children’s Research Hospital, UT Health San Antonio, The University of Chicago Medical Center, Fred Hutchinson Cancer Center, Florida Cancer Specialists & Research Institute, Invitae Corp., Clinigen Group plc, Fulgent Genetics, Dana-Farber Cancer Institute Inc., Oncology Hematology Care Inc., Enterome , National Institutes of Health Clinical Center, Progenics Pharmaceuticals Inc., Pheo Para Alliance, Saint John’s Cancer Institute
What major trends will shape the paraganglioma market during the forecast period?
Major companies operating in the paraganglioma market are focusing on developing advanced therapies such as oral hypoxia-inducible factor-2 alpha (HIF-2a) inhibitors to offer targeted therapy options for patients with paraganglioma. An oral HIF-2a inhibitor is a targeted therapy that suppresses HIF-2a activity, a key factor in tumor growth under low-oxygen conditions, helping to slow the progression of cancers like paraganglioma. For instance, in January 2025, Merck, a US-based biopharmaceutical company, announced a priority review for its supplemental new drug application for Welireg (belzutifan), which is granted by the U.S. Food and Drug Administration (FDA), a US-based government agency. It is designed for adult and pediatric patients (12 years and older) with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). The sNDA is based on objective response rate (ORR) and duration of response (DOR) data from the Phase 2 LITESPARK-015 trial.
What are the key regional dynamics of the paraganglioma market, and which region leads in market share?
North America was the largest region in the paraganglioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paraganglioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Paraganglioma Market Report 2025 Offer?
The paraganglioma market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Paraganglioma is a rare neuroendocrine tumor originating from paraganglia, clusters of cells linked to the autonomic nervous system. Typically found in the head, neck, chest, or abdomen, these tumors may produce excess hormones and pose a risk of malignancy. Early diagnosis is essential for effective management and preventing complications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21245
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
